Regulatory

Comprehensive guide to the EU's new Breakthrough Device (BtX) framework under MDCG 2025-9 and the EMA pilot program launching Q2 2026. Covers eligibility criteria, application process, benefits for manufacturers, comparison with the FDA Breakthrough Device Program, and what this means for IVD companies.

Detailed analysis of MedTech Europe's May 2026 position paper on the proposed MDR/IVDR revision. Covers breakthrough/orphan pathways, cybersecurity, AI integration, IVDR-specific concerns, and what manufacturers need to know about the coming legislative process.

Breaking down the FDA's May 2026 one-day inspection pilot that uses AI (Elsa) to target low-risk facilities. Covers how facilities are selected, what to expect during a screening inspection, how it differs from standard inspections, and what medical device manufacturers must do to stay ready.

The FDA's April 2026 real-time clinical trials initiative uses AI and cloud computing to monitor trial data as it is generated. This guide explains how the program works, the Paradigm Health platform, implications for medical device clinical investigations, and what sponsors must prepare to participate.

A complete guide to Commission Implementing Regulation (EU) 2026/977, published May 4, 2026, which sets uniform quality management and procedural requirements for Notified Bodies conducting conformity assessments under the MDR and IVDR. Covers maximum timelines, clock-stop rules, quotation transparency, re-certification procedures, and what manufacturers need to know.

A practical guide to the April 2026 MDCG updates affecting every EU medical device and IVD manufacturer. Covers MDCG 2021-24 Rev.1 classification guidance changes, EMDN v3/2026 code updates (MDCG 2026-1, 2026-2, 2026-3, MDCG 2021-12 Rev.2), the Borderline and Classification Manual Version 5, and what manufacturers must do to stay compliant.

Practical guide to building the critical-task matrix for auto-injector and pen-injector human factors validation — task identification from URRA, needle shield removal, site selection, dose confirmation, hold time, misfire recovery, training decay, disposal, use-error root cause analysis, and FDA/IEC 62366 evidence expectations.

How the EPA's 2026 proposed rollback of ethylene oxide emissions standards affects medical device manufacturers, sterilization facilities, and supply chains — the 2024 rule, proposed changes, compliance timelines, and alternative sterilization strategies.

Step-by-step playbook for responding to FDA Additional Information requests in eSTAR 510(k) and De Novo submissions — response table format, file naming, version control, section mapping, RTA vs substantive deficiencies, and traceability to original submission sections.

A systematic playbook for diagnosing and resolving EUDAMED bulk upload validation errors — covering XSD schema failures, Basic UDI-DI/UDI-DI mismatches, EMDN code issues, certificate linkage errors, DTX error codes, NB confirmation bottlenecks, and a pre-upload validation checklist.

A methodical approach to mining FDA's AI-enabled device list and 510(k) database for predicate devices — covering technological characteristic extraction, public summary limitations, weak predicate argument avoidance, and a complete predicate evaluation matrix.

Step-by-step guide to building the ASCA evidence package for 510(k) and De Novo submissions — ASCA Summary Test Report, declaration of conformity, lab accreditation status check, scope matching, withdrawn/suspended lab risk, FDA questions, and submission rescue strategies.

Practical due-diligence checklist for evaluating the FDA Third Party Review (3P510k) Program — product-code eligibility verification, Accredited Person selection, conflict-of-interest screening, eSTAR compatibility, FDA final-determination risk, timeline and cost tradeoffs, and when to avoid third-party review.

Step-by-step guide to building a dual PMSR/PSUR reporting architecture that satisfies both EU MDR/IVDR and Great Britain SI 2024/1368 requirements — data-period alignment, GB-specific content, MHRA standardized format, FSCA linkage, trend reporting, record retention, and responsible-owner mapping.

Operational guide to the invalid-result workflow for home-use and self-test IVDs — covering invalid rate targets, lay-user error coding, repeat-test instructions, IFU comprehension, customer support scripts, specimen collection errors, adverse event handling, and postmarket trending.

A comprehensive guide to MDUFA VI — the 2027-2032 FDA medical device user fee agreement covering CDRH staffing restoration, America-First fee restructuring, real-world evidence provisions, fee projections, and practical preparation strategies for device manufacturers.

Practical guide to change control for NGS bioinformatics pipelines in IVD devices — covering variant caller updates, reference database changes, threshold modifications, wet-lab/software interface validation, IEC 62304 documentation, revalidation triggers, and postmarket records.

Operational guide to converting an RUO-labeled assay or reagent into a cleared or approved IVD — covering marketing claims cleanup, distributor scripts, customer notices, historical data triage, validation bridge strategy, complaint transition, sales training, and evidence firewall construction.

Decision tree for when a software or cybersecurity update can use Special 510(k) vs Traditional 510(k) — risk analysis, V&V summary, FDA guidance, and evidence package requirements.

2026 is the most consequential year for medical device UDI compliance globally. Mandatory deadlines hit in the EU (May 28), Switzerland (July 1), Australia (July 1), and China. This guide covers every active UDI system, class-by-class deadlines, data requirements, and what happens if you miss them.